Kazia Therapeutics (KZIA) traded higher on Wednesday after Guggenheim became the latest brokerage to launch its coverage with a Buy rating based on its lead candidate paxalisib following a similar rating from Leerink Partners earlier this week.

Analyst Paul Jeng